IP Library Granted Patent US 7,432,051
Granted Patent B2
US 7,432,051 · App. 10/432,899 · Granted Oct 7, 2008

Erythropoietin and erythropoietin receptor expression in human cancer

Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,432,051
App. No.
10/432,899
Granted
Oct 7, 2008
Kind
B2
Abstract

The present invention relates to the elucidation of the role of erythropoietin and the erythropoietin receptor in the development and progression of certain solid tumors, including those found in breast, cervical, uterine, ovarian, prostate and brain cancer.

Claims (8)

1. A method of detecting a solid breast tumor in a patient comprising measuring erythropoietin or erythropoietin receptor expression in a patient sample isolated from breast tissue of the patient wherein an increased level of expression is indicative of the presence of a tumor.

2. The method of claim 1 wherein both erythropoietin and erythropoietin receptor expression are measured in the patient sample.

3. The method of claim 1 , wherein the expression is determined by measuring the level of erythropoietin or the erythropoietin receptor polypeptide.

4. The method of claim 1 , wherein the expression is determined by measuring the level of a nucleic acid encoding erythropoietin or the erythropoietin receptor.

5. The method of claim 4 , wherein the nucleic acid is amplified using polymerase chain reaction.

6. The method of claim 5 , wherein the nucleic acid is mRNA and the mRNA is reversed transcribed into DNA before amplification.

7. The method of claim 1 , wherein the sample is isolated from the mammary gland.

8. The method of claim 1 , wherein the tumor is selected from the group consisting of invasive lobular carcinoma, invasive ductal carcinoma and ductal carcinoma in situ.

Assignments (4)
CONFIRMATORY LICENSE Recorded Nov 18, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040367/0947 →
CONFIRMATORY LICENSE Recorded Nov 16, 2016
From: HENRY M. JACKSON FDN FOR THE ADV MIL/MED
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040336/0989 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2003
From: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES
To: HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE
Reel/Frame 014687/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2003
From: VERMA, AJAY
To: UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCE
Reel/Frame 014687/0523 →
Continuity (2)
Provisional Application 6025394100 · Nov 30, 2000
Related Publication 20050260580A1 · Nov 24, 2005